FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2752326755> ?p ?o ?g. }

• W2752326755 endingPage "4520" @default.
• W2752326755 startingPage "4520" @default.
• W2752326755 abstract "Abstract Background A treatment option for patients with relapsed/refractory multiple myeloma (RRMM) is pomalidomide(pom) and dexamethasone (dex), with an overall response rate (ORR) of 33% and median progression free survival (PFS) of 4.2 months. Adding the alkylatingagent cyclophosphamide(Cy) to pom and steroids improves ORR and PFS. Baz et al (Blood, 26 May 2016) combined daily pom with weekly dosing ofCy anddex (PCD), with an ORR of 64.7% and a median PFS of 9.5 months, although grade 3/4 neutropenia increased from 31% to 52%. In our experience, compared to weekly Cy, low dose daily oral Cy is better tolerated with less myelosuppression. Palumbo et al (Blood, 17 Oct 2013) in fact combined pom with alternate day dosing ofCy and prednisone, with an ORR of 51% and a median PFS of 10.4 months and a grade 3/4 neutropenia rate of 42%. However, importantly, granulocyte stimulating factor (G-CSF) and platelet transfusion support wereprohibited, resulting in a lower maximum tolerated dose of pom of 2.5 mg (vs 4 mg in the Baz) and therefore, the rates of neutropenia cannot be compared between the two studies. In the present study, we explored PCD at the doses/schedule shown in table 1 with hematologic support even in patients with baselinecytopenias. This type of metronomic therapy has demonstrated efficacy in refractory B cell malignancies, possibly because the anti-angiogenic effects of metronomic therapy may be synergetic with conventional anti-neoplastic agents. Methods This was an open label, single arm, and single center phase 2study. The primary objective was to evaluate the best ORR. Secondary objectives were to evaluate safety, clinical benefit response (CBR), PFS, and overall survival (OS). Inclusion criteria included lenalidomide refractory, pom naïve RRMM patients with at least 2 prior lines of therapy. Patients were required to have measurable disease, adequate performance status, Cr <3 mg/dL, normal hepatic function, and ANC > 1000/uL and platelets > 50,000/uL if bone marrow plasma cells were < 50%, otherwise >30,000/uL. G-CSF and platelet support were permitted during screening and study treatment if needed. Each drug was administered at the doses and schedule shown in Table 1. Results Overall, 28 evaluable patients with progressive disease (PD) at screening have been enrolled. The median age is 66 (57% > 65 yr) with a median of 3 lines of prior therapy over 5 years since diagnosis. 3 (11%) had ANC<1.5 and 2 (7%) hadplts<50,000/µL at study entry.High-risk molecular findings were present in 13 patients (46%), including 3 with del p53 and 6 with gain of 1q21 by FISH (2 with concurrentt(4;14) and 2 with concurrent del p53). With 8 patients still on study therapy, responses include 3 complete responses (CR), 7 very good partial responses (VGPR), 9 partial responses (PR), 3 minor responses (MR), 5 stable disease (SD), and 1 PD, for an ORR of 67%, CBR (i.e. MR or better) of 78% and a median PFS of approximately 14.5 months. The median OS has not been reached. The most common grade 3/4 toxicity (regardless of drug attribution) was neutropenia with 20 (71%) of subjects experienced grade 3/4 neutropenia. Importantly, there was only 1 episode of febrile neutropenia during study therapy. Grade 3/4 thrombocytopenia was seen in 25% of subjects, and 3/4 anemia seen in 18%. The most common grade 3/4 non-hematologic toxicity was pulmonary disease with Grade 3 lung infections occurring in 21% of subjects (3 viral, 2 bacterial, 1 unknown) and 1 additional grade 3 URI. Of note, all of these admissions occurred at local hospitals and none of these occurred in the setting of neutropenia. One additional pt hadpneumonitisattributed to pom requiring study discontinuation. Grade 3rashwas also observed in 14% of subjects leading to pom dose reductions. Correlative data from peripheral blood and bone marrow aspirates taken at baseline, Cycle 3 Day 15, and at disease progression from all patients will be updated at the time of conference. These include PCD-associated changesin gene expression, clonal evolution and immune microenvironment during therapy and on progression. Conclusions With toxicities similar to those in other studies, the ORR of 67% and PFS of 14 months in our study of PCD compares very favorably to pomdexas well as other triplet regimens containingCy. Disclosures Chari: Takeda: Consultancy, Research Funding; Array Biopharma: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Pharmacyclics: Research Funding; Amgen Inc.: Honoraria, Research Funding. Cho:Genentech Roche: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Research Funding; Agenus, Inc.: Research Funding; Ludwig Institute for Cancer Research: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Research Funding. Catamero:Celgene: Honoraria, Speakers Bureau. Verina:Celgene: Speakers Bureau. Jagannath:Bristol Myer Squibb: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees." @default.
• W2752326755 created "2017-09-15" @default.
• W2752326755 creator A5002010987 @default.
• W2752326755 creator A5006108161 @default.
• W2752326755 creator A5007174980 @default.
• W2752326755 creator A5011225363 @default.
• W2752326755 creator A5018920514 @default.
• W2752326755 creator A5028046297 @default.
• W2752326755 creator A5030169083 @default.
• W2752326755 creator A5030726651 @default.
• W2752326755 creator A5030998313 @default.
• W2752326755 creator A5031824922 @default.
• W2752326755 creator A5037411557 @default.
• W2752326755 creator A5066852464 @default.
• W2752326755 creator A5071001428 @default.
• W2752326755 creator A5074153548 @default.
• W2752326755 creator A5076622910 @default.
• W2752326755 creator A5082734870 @default.
• W2752326755 creator A5087202351 @default.
• W2752326755 creator A5087217740 @default.
• W2752326755 date "2016-12-02" @default.
• W2752326755 modified "2023-10-18" @default.
• W2752326755 title "A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma" @default.
• W2752326755 cites W1973091654 @default.
• W2752326755 cites W1988998251 @default.
• W2752326755 cites W1992893638 @default.
• W2752326755 cites W2059837228 @default.
• W2752326755 cites W2059876129 @default.
• W2752326755 cites W2076744879 @default.
• W2752326755 cites W2090806526 @default.
• W2752326755 cites W2133739087 @default.
• W2752326755 cites W2136541422 @default.
• W2752326755 cites W2155165473 @default.
• W2752326755 cites W2302708051 @default.
• W2752326755 cites W2326706351 @default.
• W2752326755 cites W2394652810 @default.
• W2752326755 cites W2522419283 @default.
• W2752326755 cites W2552737980 @default.
• W2752326755 cites W2560267087 @default.
• W2752326755 cites W2610269487 @default.
• W2752326755 cites W2625253716 @default.
• W2752326755 cites W2688500010 @default.
• W2752326755 doi "https://doi.org/10.1182/blood.v128.22.4520.4520" @default.
• W2752326755 hasPublicationYear "2016" @default.
• W2752326755 type Work @default.
• W2752326755 sameAs 2752326755 @default.
• W2752326755 citedByCount "3" @default.
• W2752326755 countsByYear W27523267552017 @default.
• W2752326755 countsByYear W27523267552020 @default.
• W2752326755 crossrefType "journal-article" @default.
• W2752326755 hasAuthorship W2752326755A5002010987 @default.
• W2752326755 hasAuthorship W2752326755A5006108161 @default.
• W2752326755 hasAuthorship W2752326755A5007174980 @default.
• W2752326755 hasAuthorship W2752326755A5011225363 @default.
• W2752326755 hasAuthorship W2752326755A5018920514 @default.
• W2752326755 hasAuthorship W2752326755A5028046297 @default.
• W2752326755 hasAuthorship W2752326755A5030169083 @default.
• W2752326755 hasAuthorship W2752326755A5030726651 @default.
• W2752326755 hasAuthorship W2752326755A5030998313 @default.
• W2752326755 hasAuthorship W2752326755A5031824922 @default.
• W2752326755 hasAuthorship W2752326755A5037411557 @default.
• W2752326755 hasAuthorship W2752326755A5066852464 @default.
• W2752326755 hasAuthorship W2752326755A5071001428 @default.
• W2752326755 hasAuthorship W2752326755A5074153548 @default.
• W2752326755 hasAuthorship W2752326755A5076622910 @default.
• W2752326755 hasAuthorship W2752326755A5082734870 @default.
• W2752326755 hasAuthorship W2752326755A5087202351 @default.
• W2752326755 hasAuthorship W2752326755A5087217740 @default.
• W2752326755 hasConcept C121332964 @default.
• W2752326755 hasConcept C126322002 @default.
• W2752326755 hasConcept C141071460 @default.
• W2752326755 hasConcept C142424586 @default.
• W2752326755 hasConcept C143998085 @default.
• W2752326755 hasConcept C2776063141 @default.
• W2752326755 hasConcept C2776364478 @default.
• W2752326755 hasConcept C2776694085 @default.
• W2752326755 hasConcept C2776755627 @default.
• W2752326755 hasConcept C2777063308 @default.
• W2752326755 hasConcept C2777288759 @default.
• W2752326755 hasConcept C2778524551 @default.
• W2752326755 hasConcept C2778850193 @default.
• W2752326755 hasConcept C2780401358 @default.
• W2752326755 hasConcept C71924100 @default.
• W2752326755 hasConcept C87355193 @default.
• W2752326755 hasConcept C90924648 @default.
• W2752326755 hasConcept C98274493 @default.
• W2752326755 hasConceptScore W2752326755C121332964 @default.
• W2752326755 hasConceptScore W2752326755C126322002 @default.
• W2752326755 hasConceptScore W2752326755C141071460 @default.
• W2752326755 hasConceptScore W2752326755C142424586 @default.
• W2752326755 hasConceptScore W2752326755C143998085 @default.
• W2752326755 hasConceptScore W2752326755C2776063141 @default.
• W2752326755 hasConceptScore W2752326755C2776364478 @default.
• W2752326755 hasConceptScore W2752326755C2776694085 @default.
• W2752326755 hasConceptScore W2752326755C2776755627 @default.
• W2752326755 hasConceptScore W2752326755C2777063308 @default.
• W2752326755 hasConceptScore W2752326755C2777288759 @default.
• W2752326755 hasConceptScore W2752326755C2778524551 @default.

• next